Evidence map›Paper›PMID 25750552›Full record

ReviewThe Korean journal of internal medicine2015

Roadmap for elimination of gastric cancer in Korea.

David Y Graham

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Korean journal of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Novel and Effective Therapeutic Regimens forFrontiers in cellular and infection microbiology · 2017
    Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David Y GrahamDepartment of Medicine, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX, USA.

Funding

Tissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3M
Gene Expression in Barrett's EsophagusR21DK067366 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI EL-SERAG, HASHEM B · 2005 to 2006
$296k
NIDDK NIH HHS DK067366NIDDK NIH HHS DK56338NIDDK NIH HHS P30 DK056338NIDDK NIH HHS R21 DK067366
6 · The paper itself

Abstract

Most gastric cancers are caused by infection with the common human bacterial pathogen, Helicobacter pylori. It is now accepted that gastric cancer can be prevented and virtually eliminated by H. pylori eradication and this knowledge was responsible for country-wide H. pylori eradication combined with secondary cancer prevention for those with residual risk that was introduced in Japan in 2013. Korea is a high H. pylori prevalence and high gastric cancer incidence country and a good candidate for a gastric cancer elimination program. The presence of an H. pylori infection is now considered as an indication for treatment of the infection. However, antimicrobial drug resistance is common among H. pylori in Korea making effective therapy problematic. Country-wide studies of the local and regional antimicrobial resistance patterns are needed to choose the most appropriate therapies. H. pylori and gastric cancer eradication can be both efficient and cost effective making it possible and practical to make Korea H. pylori and gastric cancer free. There is no reason to delay.

Indexed as

Anti-Bacterial AgentsDisease EradicationDrug Resistance, BacterialHelicobacter InfectionsHelicobacter pyloriHumansPrevalencePrimary PreventionRepublic of KoreaRisk AssessmentRisk FactorsStomach NeoplasmsTreatment OutcomeAnti-Bacterial AgentsCancer preventionEradication therapyHelicobacter pyloriPrimary preventionStomach neoplasms

Identifiers

PMID25750552
PMCPMC4351317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.